Verastem Q2 net product revenue $25.1M; cash runway extended into H2 2027 via $75M Oberland deal

Verastem, Inc.

2026-Q2 EPS reported -$0.81 vs consensus -$0.44 ▼ miss (-83.5%)

Net product revenue of $25.1M from AVMAPKI FAKZYNJA CO-PACK, up from $2.1M in Q2 2025.
Total revenue $40.1M (incl. $15M COPIKTRA milestone); GAAP net loss $34.7M ($0.35/share).
Cash, equivalents & investments $136.4M; proforma $201.4M after $50M Oberland closing and $15M milestone.
First patients dosed in all three TARGET-D Phase 2 trials of VS-7375; updated data expected October 2026.
Appointed Michael P. Bailey to Board of Directors; non-dilutive royalty financing with Oberland Capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.